Shoulder Innovations forecasts $68m-$70m in 2026 sales after $16.2m third quarter

Shoulder Innovations (NYSE: SI), which develops implants for shoulder replacement surgery, reported net revenue of $16.2 million for the third quarter of 2026 on 5 November. The company characterises that as growth of 38% from the same period a year earlier. It also now expects full-year 2026 revenue of $68 million to $70 million.

The product news centres on two items. The company received US Food and Drug Administration 510(k) clearance for, and launched, its N-22 humeral head, which is designed for patients with metal hypersensitivity. It also carried out its first surgeries with InSet Go, a glenoid implant, the component that sits on the shoulder-blade side of the joint. The company's material did not say how much either product contributed to sales.

On the corporate side, Shoulder Innovations announced a settlement of patent litigation with Catalyst OrthoScience, a fellow shoulder-focused business, and a partnership with ALM Ortho. The financial and legal terms of both arrangements were not available, so it is unclear what the settlement costs or permits, or how the ALM Ortho relationship will operate commercially.

Context: a 510(k) is the FDA route that lets a device reach the US market by showing it is substantially equivalent to a device already legally sold. It generally involves less evidence than a full premarket approval application.